Talon Biomarkers : Your Biomarker Discovery Engine

Precision Patient Stratification

Unfortunately, many patients who receive immunotherapy (or other drug regimens) don't respond to treatment.

​

The presence of certain immune cell subsets before/during treatment may predict whether a patient will respond to therapy.

​

Identifying these cell types is now fast, efficient, and robust with Talon Biomarkers' approach.

​

This knowledge charts a path to precision medicine.

Better Drug Development Strategy

By identifying the cell types that predict successful treatment, we can refine patient exclusion criteria in clinical trials, and help simplify the path to approval.

Talon can also measure many different immunotherapy targets at once, in order to clearly describe the cell-by-cell distribution of immune checkpoint (and other targetable) molecules. This work can be done in blood or tissue.

This can be used to smartly design combination drug therapies.

​

​

Companion Diagnostics

​

Companion diagnostics are tests developed with a drug that help define ideal patient populations for treatment.

​

Our biomarker discovery engine provides a robust platform for discovery of new biomarkers that can be developed into companion diagnostics.

​

Without our engine, companies are left to rely on a random, hit-or-miss strategy of licensing biomarkers discovered in academic research laboratories. Our platform provides a forward looking strategy to participate in this important and lucrative market.

 Maximal Information from Samples

The samples collected in a trial are precious.  They represent the sum of years of organizational and clinical effort, and capture a specific moment in patient's disease.

​

To honor that investment, we have a responsibility to obtain as much data as possible from samples.

​

Talon's technology platform is designed not just to maximize the data we obtain, but to obtain it robustly, and to mine it as comprehensively as possible.